

Curriculum Vitae

MOHAMED EI MUBASHER, Ph.D.

Office Telephone: 214-648-1041; Office Fax: 214-64810481

E-Mail: Mohamed.Mubasher@UTSouthwestern.edu

The University of Texas School of Public Health

Dallas Regional Campus

Division of Biostatistics

6011 Harry Hines Blvd. V8.112 Dallas Texas 75390-9128

Higher Education

Date **Degree**

Institution & Location

1990 Ph.D. (Biostatistics) Department of Biostatistics, University of Pittsburgh, Pittsburgh PA, USA

1983 MA (Applied Statistics) Department of Mathematics and Statistics, University of Pittsburgh, Pittsburgh, PA , USA

1982 M.A. (ABD) (Mathematics) Department of Mathematics and Statistics, University of Pittsburgh, Pittsburgh, PA, USA

Appointments

(Academic Appointments)

Dates **Title**

Institution & Location

2003 - Associate Professor of Biostatistics; University of Texas; School of Public Health; Division of Biostatistics; Dallas Regional Campus

1999- 2003 Associate Professor, State University of New York, Division of Epidemiology ,Preventive Medicine, Stony Brook NY

1994-1999 Research Assistant Professor, State University of New York

1990-1993 Asst. Professor Wayne State University (WSU) Division Of Hematology and Oncology , School of Medicine, Detroit, MI

1984-1990 Research Assistant Statistician, University of Pittsburgh, Dept. of Biostatistics , University of Pittsburgh, Pittsburgh PA,

1981-1983 Teaching Assistant, Dept. of University of Pittsburgh, Mathematics and Statistics Pittsburgh, PA

Other Appointments

1998-2003 Director of the biostatistical data management and computing core, General Clinical Research Center, Department of Preventive Medicine, University of New York at Stony Brook, Stony Brook, NY

1994-2003 Advisory Committee of General Clinical Research Center, School of Medicine, University of New York at Stony Brook, Stony Brook, NY

1994-2003 Biostatistician, General Clinical Research, School of Medicine, University of New York at Stony Brook, Stony Brook, NY

1993-1994 Group Leader, Cytokine Development Unit, Sandoz Pharmaceuticals Corp., East Hanover, NJ

1990-1993 Advisory Committee Member, Meyer L. Prentis, Comprehensive Cancer Center (MLPCCC), Detroit, MI

1990-1993 Biostatistician, Multi-Disciplinary Lung Cancer Program, Division of Hematology/Oncology, WSU School of Medicine, Detroit, MI

1986-1989 Biostatistical Consultant (part time), Department of Biostatistics , University of Pittsburgh, Pittsburgh, PA

Professional Practice & Services

1994-2003 Co-investigator/ PI in two major National Eye Institute-sponsored clinical trials in the ophthalmological/ optometric research areas. Co-designed and oversaw the conduct of these trials. Also provided biostatistical input, while interacting and collaborating with epidemiologists and clinicians through out the designing, conduct and analyses phases of these trials. Responsible for devising

statistical stopping guidelines criteria pertaining to these grants. Assisted in carrying out the recommendations of the Data Safety and Monitoring Committee (DSMC/DSMB) regarding the monitoring and analyses issues, which also includes participation in the presentation and interpretation of results to NEI site visitors and DSMC members. Finally, responsible for devising and implementing Data Quality Assurance mechanisms and general monitoring of data integrity and management activities, final statistical analyses plans, interpretation and co authoring findings. Additional responsibilities included supervising, guiding and interacting with other statisticians and data managers.

1994-2003 Provided design and biostatistical input and collaborated in research and publication of studies fostered by the general Clinical Research Center (NIH funded grant). The grant provided core biostatistical data management and computer input to inter-disciplinary projects in the medical school at Stony Brook. Thirty-four clinical and basic science projects are part of the initial core service.

1994-2003 Directed the Biostatistical, data management and computing core, which responsibilities include a) overseeing Core's personnel, b) devising and implementing short and long term plans of the Core, c) statistical design, conduct and analysis methods and d) site visit presentations, defense and justification of the biostatistical, computing and data management techniques.

1994-1997 Provided biostatistical input to the Convergence Insufficiency and Reading Study (CIRS) group. This included design, conduct analysis (as well as overseeing data management) and presentation of results at general optometry meetings and conferences. CIRS studies involved pilot, reliability and validity determinations.

1995-1996 Provided biostatistical input to a major grant proposal aimed at determining the efficacy of antibiotic therapy among patients with chronic Lyme disease. The proposal involved conducting a multi-center clinical trial.

1998-1999 Collaborated with Chairs of Surgery and Preventive Medicine in the designing aspects of a cardiovascular clinical trial aimed at comparing several surgical procedures; [Carotid Endarterectomy](#) Bi-Pass Staging Trial (CABEST).

1993-1994 Assisted the director of the Cytokine Development Unit, Sandoz Pharmaceuticals Corporation in the general provision of Design, biostatistical input to the medical experts and Clinical research Scientists in both clinical as well as preclinical aspects of Cytokine discovery and development. This included statistical writing/review of design, conduct, and proposed analysis of protocols and laboratory studies. Additionally, performed and reported statistical analysis. Furthermore, interacted with Food and Drug Administration statisticians

throughout the drug approval process and assisted in writing the statistical section(s) of future Product Licensing Application.

1990-1993 Assisted the Director of Biostatistics, Division of Hematology and Oncology, WSU Medical School, Detroit MI, in the general provision of biostatistical input throughout the Division. This included statistical review of design, conduct, analysis and reporting for cancer research protocols and laboratory studies, collaboration and consultation with clinicians and basic scientists and assisting in grant proposals development, submission and defense. Other responsibilities included teaching/seminar duties of biostatistical topics.

1990-1993 Assisted Biostatistician-in-chief of the Meyer L. Prentis Comprehensive Cancer Center (MLPCCC), Detroit, MI, in the general provision of biostatistical input, including consultative/collaborative services as well as protocol development and grant submission throughout the MLPCCC.

1990-1993 Assisted the Director of the Division of Hem/Onc WSU Medical School, Detroit, MI in the development of the Multi-Disciplinary Lung Cancer Program (MDLCP) including data collection forms and the use of a computerized database, to account for all clinical and socio-economic indicators of all MDLCP patients.

1984-1990 Provided biostatistical, programming and data management input to Senior Faculty statisticians at the National Surgical Adjuvant of Breast and Bowel Cancer Project, at the Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA. This included analysis and reporting of interim results of cancer adjuvant therapy clinical trials.

Summer 1990 Statistical Consultant for RADON Project, physics Department, University of Pittsburgh, Pittsburgh, PA.

Professional & Scientific Societies

<u>Organization</u> <u>Membership</u>	<u>Date of Initial</u>	<u>Leadership Position(s)</u>
Biometric Society, ENAR	March, 1990	- present
American Statistical Association	March, 1990	- present
Society for Clinical Trials (SCT) 1993 Trials	April, Session Chair, Statistical Methods in Clinical	

Association for Research in Vision and Ophthalmology
(ARVO) Journal Reviewer for IOVS

International Perimetric Society (IPS)

Association of GCRC Statisticians (AGS)

National/ Professional Other Duties

1999-present Consultant/ study section Reviewer for the USA National Institute of Health (NIH) on research, statistical design and methodology. Part of a Special Review Sessions held by the Nation Eye Institute to scientifically evaluate grant proposals in the areas of Ophthalmology and optometry.

Academic & Professional Honors

April 1999 Certificate of appreciation, State University of New York, Stony Brook, Health Sciences Center

Research Support: Grants, Contracts

From To Project & Sponsor

1994-2003 Co-Investigator and Biostatistician for the Early Manifest Glaucoma Trial (EMGT) 42%; NEI Funded Grant; P.I. M.C. Leske, SUNY @ Stony Brook, NY

1994-2003 Co-Investigator /PI and Biostatistician the Correction Of Myopia Evaluation trial (COMET) 40%; NEI Funded grant; P.I.: L Hyman

1997-2003 Co-Investigator and Biostatistician for the General Clinical Research Center, 10% salary support, NIH Grant; P.I.: N. Edelman

1997-2000 Co-Principal Investigator and Biostatistician for Vasoactive Intestinal Peptide in the Adult Respiratory Distress Syndrome. 5% funded project; P.I.: S.I. Said

1999-2003 Co-Investigator and Biostatistician for Coronary Bypass Endarterectomy Staging Trial (CABEST). 5% effort. NIH funded grant, P.I. John Ricotta

Previous

1991-1993 Biostatistical input for Clinical and Laboratory Studies; 15% salary support; portion of NCI Cancer Center Support Grant; P.I. L. Baker.

1992-1995 Biostatistical Core input; 15% salary support; P.I.K. Pienta; "The Nuclear Matrix as a Cancer Chemotherapy Target"; NCI

1992-93 Hussein, M.E. WSU Small Research Grant

1993-1995 Biostatistical input; 10% salary support; P.I. M. Simon "a Study of the Cost of Clinical follow-up in Women with Early Stage Breast Cancer; Michigan Health Care Education And Research Foundation

1991-1994 Biostatistical input for M. Simon Grant Proposal Development of Evaluation of follow-up of Women with Early Breast Cancer, WSU Medical School

Grant proposals

Funded

- 1) Lipsky S; 06/30/2006-06/30/2009;K30 Award;\$300,000;5%;Co-PI
- 2) Caetano Raul P.I : NSCOR (The NSCOR program was established to advance knowledge in biological and biomedical sciences and technology, with the ultimate application of this knowledge to enable human space flight and long term planetary missions). Direct costs \$170,702.00, indirect costs \$41,823.00; 20%;Co-PI
- 3) Carig Field ; R01: 6/30/2005-06/30/2010; Multi-disciplinary approach to reduce injury and alcohol use; \$1,220,000; 10%

Pending

2006- 2008 Mohamed Mubahser, P.I Analyses of Dallas Cohort Glaucoma Study; submitted to NIH ; 6/30/2006-6/30/2008. 30% effort; \$300,000

Zimmern P; 03/30/2006-3/30/2008; \$300,000; 20% Co-PI;(Feasibility of preventive approach To Pelvic Organ

Courses Directed/Taught

Spring 2006 Taught Statistical Methods in Clinical Trials as par of the elective requirements for the UT SPH MPH Program.

Fall 2005 Taught a core course requirement of Introduction to Biostatistics for the UT SPH MPH Program.

Spring-Summer 2005 Taught Intermediate Biostatistics/special topics in Biostatistics, and held practicum and thesis supervision as part of requirements for the UT SPH MPH Program.

Fall 2004 Taught Intermediate Biostatistics/mathematical statistics, requirements for the UT SPH MPH Program.

Fall and spring 2003 Taught two courses on Statistical Methods in Clinical Trials as part of the requirements for the UT SPH MPH Program.

1994-Spring 2003 Taught part of the introduction to preventive medicine course that also involved holding series of seminars on epidemiological topics and interpretation of published research to first year medical students.

1998-2000 Taught mathematical statistics courses at State University of NY, Applied Math and Stat department.

Fall 1992 Co-wrote the Biometrics Exam questions for the Ph.D students at WSU Graduate Program of cancer biology, Detroit, MI.

1991-1992 Developed a curriculum for Biostatistical topics to be taught to Hem/Onc Fellows and Graduate Oncology students as part of the fellowship-training program of the MLPCCC, Detroit, MI.

Students Advising 2004-2005: 12 Students (8 primary and 4 secondary)

Dissertations Co-Supervising/Supervised

2005-2006-Jiguo Wang; UT Houston, Dallas regional campus, MPH program.

2004-2005 Sammy Dick_Onuoha ; UT Houston, Dallas regional campus, MPH program.

2005 -Annita Anderfuren; UT Houston, Dallas regional campus, MPH program.

2005- Amparo Bernal ; UT Houston, Dallas regional campus, MPH program.

2003- 2004 Amit Gupta, UT Houston, Dallas regional campus, MPH program.

1998 - 2002 James Mancuso, Department of Applied Mathematics & Statistics, SUNY at Stony Brook, NY

1997-2001 Kwisung Hwang, Department of Applied Mathematics & Statistics, SUNY at Stony Brook, Stony Brook, NY

1994-1997 Biostatistical teaching for first year medical students, as part of Introduction to Preventive Medicine Course, Stony Brook.

Students for Summer Internship & Medical Research Guidance

Summer 1996 Fang Wan, Dept. of Applied Mathematics & Statistics, Course #AMS 575, SUNY at Stony Brook, Stony Brook, NY

Summer 1999 Xinhong, Feng, Dept. of Applied Mathematics & Statistics, Course #AMS 575, SUNY at Stony Brook, Stony Brook, NY

1998-1999 Moitri Chowdhury Savard, MD, "Class of 1999", SUNY at Stony Brook, School of Medicine, Mentor and Supervisor in conducting a study entitled "The Determinants of Acceptance of Prenatal HIV Testing", as part of her medical research requirement.

1999-2002 Seminars on Statistical and epidemiological topics and interpretation of published research to first year medical students, Introduction to Preventive Medicine Course.

SERVICE (Selected)

1) consultant on designing, conducting and analyzing an internationally conducted study in China evaluating the effects of probiotics in preventing/delaying flu-like symptoms among preschoolers (2006).

2) Consultant on composition of an advisory committee for NIH, reviewing and formulating recommendations on submitted studies for funding in the Ophthalmologic area (2006).

3) In Dallas, I am serving as a mentor for a junior faculty in their K-award in the area of intimate partners violence (2005-2008)

4) Recommended reviewers for Investigative Ophthalmology & Visual Science (IOVS, 2006),

- 5) Analyzed data on safety of seat belts conducted by Parkland Trauma Center in Dallas and funded by the CDC (2006)
- 6) Assisted faculty member in conducting a funded study by devising a randomization scheme for subjects enrollment (2006)
- 7) Collaborated with faculty members at UT southwestern medical center on two applications at Urology (2006)
- 8) Assisted a faculty at Dallas in designs and writing of proposed applications for funding and analysis of existing data (2006).

Publications (Selected)

1. Hussein ME, Hyman L, Leske MC and the EMGT Group. Analysis of agreement data beyond kappa: application of log linear modeling to evaluate agreement in disc photograph gradings. *Controlled Clinical Trials* 1996;17(25):A39.
2. Hussein ME, Hyman L, Leske MC, et al. Cox proportional hazard model with tied events vis-à-vis logistic regression when modeling dichotomous outcomes. *Controlled Clinical Trials* 1998;19:32.
3. Hussein ME, Holmin C, Hyman L, Leske MC, Heijl A, Bengtsson B, and the EMGT Group. Flicker chronoscopy, side-by-side and disc pathology gradings in a clinical trial: ARVO Abstracts. *Invest Ophthalmol Vis Sci* 1996;37:5000.
4. Hussein ME. Use of Two Successive Rejection Rule for Stopping Phase III Cancer Clinical Trials. *Proceeds of the Annual Biometric Society Meeting for East North American Region (ENAR) in Houston TX, 1991.*
5. Hussein ME, Heilbrun L. Use of Two Successive reaction Rule to Stop a Phase II Trial. *Published in the Proceeds of ASA Annual Meeting, 1993.*
6. Flaherty L, Hussein ME, Liu PY, Smith D, Sondak V. Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility (Meeting abstract). [Meeting Abstract. Multicenter Study. *Clinical Trial, Phase II. Clinical Trial*] *Proc Annul Meet Am Soc Clin Oncol.* 13:A1352, 1994. Abstract/Complete Record

7. Al-Sarraf M, Hussein ME, Head and Neck Cancer: Future Prospects of Adjuvant Chemotherapy. *Cancer Investigation*. 13(1), 41-53 1995.
8. Zalupski MM, Ryan J, Hussein ME, Baker LH. Systemic Adjuvant Chemotherapy for Soft Tissue sarcomas of the Extremities. *Surgical Oncology Clinics of North America*, 2(4):621-637, 1993.
9. Crissman JD, Sakr WA, Hussein ME and Pontes E. DNA Quantitation of Intraepithelial Neoplasia and Invasive Carcinoma of the Prostate. *Prostate* 1993;22:155-162.
10. Rouse MW, Hyman L, Hussein ME, Solan H. Frequency of convergence insufficiency in optometry clinic settings. Convergence Insufficiency and Reading Study (CIRS) Group. (Clinical Trial. Journal Article. Multicenter Study. Randomized Controlled Trial) *Optometry & Vision Science* 1998;75(2):88-96.
11. Rouse MW, Hyman L, Hussein M, Solan H. Frequency of convergence insufficiency in optometry clinic settings. Convergence Insufficiency and Reading Study (CIRS) Group. *Optometry & Vision Science* 1998;75:88-96.
12. Rouse, MW, Hyman L, Hussein M, et al. How do you make the diagnosis of convergence insufficiency?: survey results. *Journal of Optometric Vision Development* 1997;28:91-97.
13. Rouse MW, Hyman L, Hussein ME, and CIRS Group. How do we make the diagnosis of convergence insufficiency? Survey Results. *Journal of optometric vision development*, Volume 28/Summer 1997.
14. Simon MS, Hoff M, Hussein ME, Martino S, and Walt A. An Evaluation of Clinical Follow-Up In Women with Early Stage Breast Cancer Among Physicians Members of The American Society of Clinical Oncology. *Breast Cancer Research and Treatment* 1995;32:41-45.
15. Simon MS, Stano M, Hussein ME, Hoff M, and Smith D An Analysis of The Cost of Clinical Surveillance after Primary Therapy for Women with Early Stage Invasive Breast Cancer. *Breast Cancer Research and Treatment* 1996;37:39-47.
16. Al-Katib A, Mohamed R, Hussein ME, Dan M, Akhtar A, Petit G and Sensenbrenner L. Bryostatins 1-Induced Hairy Cells Features on Chronic Lymphocytic Leukemia Cells in Vitro. *Exp. Hematology* 1993;21:61-65.

17. Smith MR, Khanuja PS, al-Katib A, Bishop CR, Andersen J, Hussein ME, Karanes C. Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease. (Journal Article) *Cancer* 1994;73(4):1264-9.
18. Zalupski MM, Maciorowski Z, Ryan JR, Ensley JF, Hussein ME, Sunderson AS and Baker LH. DNA Content Parameters of Paraffin Embedded Soft Tissue Sarcomas: Optimization of Retrieval Technique and Comparison to Fresh Tissue. *Cytometry* 1993;4(14):327-333.
19. Zalupski MM, Ryan JR, Ensley JF, Maciorowski Z, Pietraszkiewicz H, Hussein ME, Kukuruga M, Sunderson AS and Baker LH. Development and Optimization of Tissue Preparative Methodology for DNA Content Analysis of Soft Tissue Neoplasm. *Cytometry* 1993;14:922-930.
20. Ratanatharathorn V, Karanes C, Uberti J, Lum L, de Planque MM, Hussein ME, et al. Busulfan-Based Regimens and Allogeneic Bone Marrow transplantation in Patients with Myelodysplastic Syndromes. *Blood* 1993;81(8):2194-2199.
21. Ratanatharathorn V, Karanes C, Uberti J, Lum L, Abella S, Dan M, Hussein ME and Sensenbrenner LL. Phase I study of Alpha-Interferon Augmentation of Cyclosporine-Induced Graft VS Host disease in recipients of autologous Bone Marrow Transplantation. *Bone Marrow Transplantation* 1994;13(5):625-30.
22. Zalupski MM, Hussein ME, Ryan, JR and Baker LH. Adjuvant Chemotherapy for Extremity of Soft Tissue Sarcoma: A Meta-analysis of Randomized Clinical Trials Resubmitted to the Journal of National Cancer, August 1998.
23. Leske MC, Hyman, L Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. *Amer J Ophthalmol* 1999;127:623-626.
24. Hussein ME, Hyman L, Leske MC and the EMGT Group. Analysis of agreement data beyond kappa: application of loglinear modeling to evaluate agreement in disc photograph gradings. *Controlled Clinical Trials* 1996;17(2S):60S.
25. Leske MC, Hyman L, Hussein M, Heijl A, Bengtsson B. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Letter to the editor. *Amer J Ophthalmol* 1999;127:623-626.

26. Leske MC, Heijl A, Hyman L, Bengtsson B, Hussein M. Corneal Thickness and Measured IOP. Letter to the Editor. *Ophthalmol* 2000;107:1803.
27. Hussein ME, Mancuso JP, Hyman L, Leske MC. Evaluating visual field change in glaucoma clinical trials. *Society for Clinical Trials* 2001 abstract. (In Press).
28. Hussein ME, Gwiazda J, Hyman L, and the COMET Group. Reliability of measurements of phoria and accommodation in the Correction of Myopia Evaluation Trial (COMET), *Invest Ophthalmol & Vis Sci* 2001;42(4):S391.
29. Hyman L, Gwiazda J, Marsh-Tootle WL, Norton T, Hussein M and the COMET Group. The correction of myopia evaluation trial: design and general baseline characteristics. (Submitted).
30. Manny RE, Hussein M, Grice K, Scheiman M, Kurtz D, Niemann K, Zinzer K, the COMET Group**. Tropicamide 1% as a cycloplegic agent in the Correction of Myopia Evaluation Trial (COMET). *IOVS* August 2001.
31. Marsh-Tootle W, Gwiazda J, Hyman L, Hussein M, Norton T, and the COMET Group. Refractive and axial measures at baseline in children enrolled in the Correction of Myopia Evaluation Trial (COMET). (Submitted)
32. Hussein M, Hyman L, Leske MC. Using bootstrap methods to improve the precision of estimates of visual field change. *Society for Clinical Trials* May 1999.
33. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, **Hussein M**; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. *Arch Ophthalmol* 2002;120:1268-79.
34. Heijl A, Leske MC, Bengtsson B, Bengtsson B, **Hussein M**; Early Manifest Glaucoma Trial Group. Measuring visual field progression in the Early Manifest Glaucoma Trial. *Acta Ophthalmol Scand.* 2003;81:286-93
35. Leske MC, Heijl A, **Hussein M**, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. *Arch Ophthalmol* 2003;121:48-56.
36. Gwiazda J, Hyman L, **Hussein M**, Everett D, Norton TT, Kurtz D, Leske MC, Manny R, Marsh-Tootle W, Scheiman M. A randomized clinical trial of progressive addition lenses versus single vision lenses on the progression

- of myopia in children. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1492-500.
37. Gwiazda JE, Hyman L, Norton TT, **Hussein** ME, Marsh-Tootle W, Manny R, Wang Y, Everett D; COMET Group Accommodation and related risk factors associated with myopia progression and their interaction with treatment in COMET children. Invest Ophthalmol Vis Sci.2004 Jul;45(7):2143-51.
38. Kurtz D, Manny RE, Hussein M, the COMET Group**. Variability of the ocular components measurements in children using A-Scan ultrasonography. Optom Vis Sci; 2004 Jan;8(1):35-43.
39. Hyman L, Gwiazda JE, Hussein (MUBASHER); Norton TT, ME, Wang Y, Marsh-Tootle W, Everett D; COMET Group. Relationship of Age, Sex and Ethnicity with Myopia Progression and Axial Elongation in COMET. ARCH OPHTHALMOL/VOL.123, JULY 2005.

Accepted

39. Mubasher (Hussein) ME. Use of Two Successive Rejection Rule for Monitoring Phase III Clinical Trials. (August, 2006)
40. Mubasher (Hussein) M, Using bootstrap methods to improve the precision of estimates of visual field change. (July,2006)

Submitted

41. Mubasher (Hussein) ME. Sample Size and Power for Phase II/III Clinical Trials based on variable accrual and hazard rates. Statistics in Medicine (July, 2006)
42. Mubasher (Hussein) . Analysis of agreement data beyond kappa: application of loglinear modeling to evaluate agreement in disc photograph gradings. Invest Ophthalmol Vis (July,2006)
43. Mubasher (Hussein) ME, Cox proportional hazard model with tied events vis-à-vis logistic regression when modeling dichotomous outcomes. Statistics in Medicine (August, 2006)

Books and Chapters

Hussein ME, contributor. Surgical Oncology Clinics of North America, Soft Tissue Sarcoma of the Limbs. W.B. Saunders Company, Philadelphia, PA, Vol 2, #4, 1993.

Hussein ME, Book Review: Medical Statistics, A Commonsense Approach, Second Edition, Campbell MJ and Machin D, John Wiley and

Sons Publications, 1993.